Compare Inovio Pharmaceuticals Inc (INO) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Wendys Co — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Wendys Co trades at $6.23 (market cap $1.19B). The key difference: Wendys Co is far larger — about 10.6× Inovio Pharmaceuticals Inc's market cap, and Wendys Co pays a 4.49% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Wendys Co for 77 Days on average.
| INO | WEN | |
|---|---|---|
Market Cap | $112.19M | $1.19B |
Volume | 3,201,278 | 5,622,905 |
Sector | Health | Consumer Cyclical |
52-Week High | $2.60 | $9.33 |
52-Week Low | $0.66 | $6.10 |
Typical Hold Time | 43 Days | 77 Days |
Enterprise Value | $83.51M | $4.92B |
Dividend Yield | — | 4.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.
Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.
Wendy's (WEN) trades at $6.22, up 1.8% today but remains in a bearish technical trend with declining fundamentals. Revenue has stagnated around $2.2B, while net income fell to $165M in 2025, with a projected drop to $126M in 2026. The stock appears undervalued with a P/E of 9.45 and P/S of 0.54, but faces headwinds from a major franchisee bankruptcy and six consecutive quarters of same-store sales declines.
The outlook is cautious due to operational challenges and high debt, though the low valuation and consistent dividend offer some support. Analyst consensus is a 'Hold' with a $7.58 price target, reflecting skepticism about near-term recovery. Key risks include competitive pressure, execution missteps, and macroeconomic strain on consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
